Annotation Detail
Information
- Associated Genes
- NTRK1
- Associated Variants
- NTRK1 NTRK1 FUSIONS NTRK1 NTRK1 FUSIONS
- Associated Disease
- cancer
- Source Database
- CIViC Evidence
- Description
- Results from a phase I study show that the TRK inhibitor LOXO-101 is well tolerated and effective, with patients whose tumors bear NTRK fusions responding well and durably to this targeted therapy. This publication reported results from an AACR meeting for an ongoing study that had enrolled six patients with NTRK fusions, three of whom could be evaluated at the time. Each had a different, heavily pretreated advanced disease: soft-tissue sarcoma; gastrointestinal stromal tumor (GIST); and MASC.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/2953
- Gene URL
- https://civic.genome.wustl.edu/links/genes/3983
- Variant URL
- https://civic.genome.wustl.edu/links/variants/419
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Cancer
- Evidence Direction
- Supports
- Drug
- Larotrectinib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26603524
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Larotrectinib | Sensitivity | true |